# Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

> **NCT02095314** · PHASE2,PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 399 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Pentavalen

## Key facts

- **NCT ID:** NCT02095314
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-12
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095314, "Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02095314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*